1. Pink Sheet
  2. >>R&D

Wellcome Trust Makes AMR Strategic Priority After Funding O'Neill Review

 
• By Sten Stovall

Britain's well-endowed and influential Wellcome Trust which co-funded the O'Neill Review on how to tackle antimicrobial resistance has now made AMR one of its strategic priorities and aims to raise its profile with it. Wellcome policy head Ed Whiting outlines next steps in an interview with the Pink Sheet.

Wellcome Trust – the second largest charitable foundation in the world and co-founder of Human Genome Project – has made drug-resistant infections one of its strategic priorities and plans to use its political independence and financial power to maintain momentum built by the UK's O'Neill AMR Review, which it co-funded, according to the trust's policy head Ed Whiting.

The decision to make antimicrobial resistance a strategic priority was formally taken at the end of 2016 by the board of Wellcome Trust, which uses its £20.9 billion investment portfolio to, among other things, fund innovative science

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.